Markets · 1 sources covering this

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·3h ago
Galderma Slumps After FDA Turns Down Botox Rival Relfydess
Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/db3f31e02be05d806162dc6fe94c6014b2669d89"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Galderma Slumps After FDA Turns Down Botox Rival Relfydess"></iframe>

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

How 1 sources are covering this

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

More from Markets

Anthropic gets all-clear to let foreigners use latest model ahead of crucial IPO

Bad Loan Investor APS Eyes €3.3 Billion of Portfolio Deals

UK Retailer TG Jones Restructuring Plan Approved by London Court

Wall St. Women Trade Day Jobs for Lucrative Online Fame

Reader

Trust & legal

Across the network